Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
Date
2007
Authors
Wirth M.
Tyrrell C.
Delaere K.
Sanchez-Chapado M.
Ramon J.
Wallace D.M.A.
Hetherington J.
Pina F.
Heyns C.F.
Navani S.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.
Description
Keywords
antiandrogen, bicalutamide, placebo, adult, advanced cancer, aged, arthralgia, arthritis, article, asthenia, backache, cancer growth, cancer localization, cancer survival, clinical trial, constipation, controlled clinical trial, controlled study, disease free survival, double blind procedure, drug efficacy, drug eruption, drug fatality, drug tolerability, drug withdrawal, early cancer, follow up, gynecomastia, hematuria, hernia, hot flush, human, hypercholesterolemia, impotence, libido, liver function test, major clinical study, male, mastalgia, metastasis potential, multicenter study, multimodality cancer therapy, overall survival, pain, patient care, priority journal, prostate cancer, prostatectomy, randomized controlled trial, risk reduction, side effect, somnolence, urinary tract infection, urine incontinence, weight gain, Anilides, Antineoplastic Agents, Carcinoma, Chemotherapy, Adjuvant, Combined Modality Therapy, Disease-Free Survival, Double-Blind Method, Follow-Up Studies, Humans, Male, Nitriles, Placebos, Prostatectomy, Prostatic Neoplasms, Radiotherapy, Survival Analysis, Tosyl Compounds, Treatment Outcome
Citation
Prostate Cancer and Prostatic Diseases
10
1
10
1